Researchers have found in the phase II SOLSTICE trial that the investigational combination of tobevibart plus elebsiran demonstrated antiviral activity in patients with chronic hepatitis D virus (HDV) infection. At 24 weeks, 47% of patients on the dual therapy and 70% of those on tobevibart alone achieved both ALT normalization and a significant reduction or clearance of HDV RNA, suggesting promising efficacy for these new treatment approaches. The study was published in The New England Journal of Medicine by Tarik A. and colleagues.

Chronic infection with the hepatitis D virus, one of the most aggressive forms of viral hepatitis, is often characterized by a rapid progression of liver fibrosis to cirrhosis and liver failure. HDV depends on the presence of HBsAg for replication, which ma

See Full Page